Objective tumor responses and stable disease continue to be seen in the India trial. As of July 12, 2012, 63 patients got survived at least 3 months and experienced at least one follow-up CAT scan to determine tumor response. Tumor responses included: 5 comprehensive responses : 3 in the ADXS only group; 2 in the ADXS+ cisplatin group. 6 partial responses : 3 in the ADXS alone group; 3 in the ADXS+ cisplatin group. A complete response is thought as 100 percent elimination of tumor burden. A partial response is definitely thought as 30 percent or even more reduction in tumor burden. In 2012 June, Advaxis reported 4 full responses and 5 partial responses. We are very happy to observe a continuing positive pattern in patient survival and objective tumor responses as the study continues and the data mature, commented Dr.Related StoriesNitric oxide released through nanotechnology could be a new way to take care of, prevent acneMallinckrodt subsidiary to obtain Therakos for $1.325 billionNew portable system can create life-saving Simply no from air through electrical spark’We have become pleased with the results of the study as it demonstrates that AFECTAIR has the potential to effectively deliver a medical gas directly to a critical care patient, while reducing the amount of medical gas needed to achieve a target dose,’ said Dr.